Stryker Corp. has spoken out and confirmed it is not in discussions with Boston Scientific Corp. about a potential takeover bid. In quashing the rumors about a deal, Stryker's share price – which has been sliding over the two days of escalating speculation – has double backed and jumped up 6% to surpass $173 during trading on June 13, hours after the company issued its official statement.
Prior to Stryker's statement, the general consensus from analysts was that a Stryker-Boston Scientific combination – while certainly creating a company with significant
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?